Geron Corporation published a document on outcomes of imetelstat therapy in patients with ring sideroblast-negative lower-risk myelodysplastic syndromes from the pooled Imerge study populations. The document provides insights into the limited treatment options available for lower-risk myelodysplastic syndromes, particularly for patients ineligible for erythropoiesis-stimulating agents or whose disease is relapsed or refractory to these agents. The full document can be accessed through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.